GenSight Biologics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Laurence Rodriguez
Chief executive officer
€510.3k
Total compensation
| CEO salary percentage | 55.85% |
| CEO tenure | 1.8yrs |
| CEO ownership | n/a |
| Management average tenure | 3.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?
Dec 22
Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?
Sep 20Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?
Aug 17Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt
Aug 04GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 14GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -€15m |
| Mar 31 2025 | n/a | n/a | -€15m |
| Dec 31 2024 | €510k | €285k | -€14m |
Compensation vs Market: Laurence's total compensation ($USD599.06K) is above average for companies of similar size in the French market ($USD337.67K).
Compensation vs Earnings: Insufficient data to compare Laurence's compensation with company performance.
CEO
Laurence Rodriguez (57 yo)
Mrs. Laurence Rodriguez is Chief Executive Officer of GenSight Biologics S.A. from December 21, 2023 and has been its Director since January 12, 2024. Ms. Rodriguez has many years of experience in the life...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | €510.28k | no data | |
| Scientific Founder | no data | no data | no data | |
| Scientific Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Financial Officer | 1.8yrs | no data | no data | |
| Chief Technical Officer | 3.5yrs | no data | no data | |
| Consultant | 8yrs | no data | no data | |
| Chief Medical Officer | 6yrs | no data | no data | |
| Chief Technical Officer of Medical Device | 4.3yrs | no data | no data |
Experienced Management: SIGHT's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | €510.28k | no data | |
| Scientific Founder | 13.5yrs | no data | no data | |
| Scientific Founder & Chairman of Scientific Advisory Board | 13.5yrs | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | 13.5yrs | no data | no data | |
| Representative Director | 6.3yrs | no data | no data | |
| Independent Director | 1.4yrs | €30.00k | no data | |
| Independent Director | 6.3yrs | €22.50k | no data | |
| Independent Director | 8.5yrs | €22.50k | no data | |
| Independent Director | 5.1yrs | €30.00k | no data | |
| Independent Director | 4.5yrs | €30.00k | no data |
Experienced Board: SIGHT's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 16:01 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GenSight Biologics S.A. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Guillaume Cuvillier | Gilbert Dupont |